MedTrace Logo

Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder

NCT06221930 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2025-01-27

No results posted yet for this study

Summary

In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis. Inclusion criteria are: male, female or non-binary, age 18-65, diagnosis of ADHD, elevated levels of ADHD symptoms (score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1), stable treatment for at least 30 days at time of inclusion, sufficient German skills, and consent to participation. Exclusion criteria are: Diagnosis of any other severe psychiatric disorder and plans to change treatment in the upcoming three months. Patients will be randomized and allocated to either an intervention group, receiving access to attexis in addition to TAU, or a control group, receiving access to TAU only. Primary endpoint will be self-rated ADHD symptomatology, assessed via the ASRS v1.1, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, self-esteem, work and social functioning, and health-related quality of life.

Conditions

  • Adult Attention Deficit Hyperactivity Disorder

Interventions

BEHAVIORAL

attexis

Participants will receive access to the digital health intervention attexis in addition to TAU.

Sponsors & Collaborators

  • Zentrum für Integrative Psychiatrie Kiel

    collaborator UNKNOWN

  • University Hospital, Saarland

    collaborator OTHER

  • Gaia AG

    lead INDUSTRY

Principal Investigators

  • Eva Fassbinder, MD · Zentrum für Integrative Psychiatrie Kiel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2024-09-25
Completion
2024-12-25

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06221930 on ClinicalTrials.gov